An­a­lysts’ top 10 biotech takeover tar­gets are con­cen­trat­ed in two key ar­eas

CEO Schwan of Swiss drug­mak­er Roche ad­dress­es the an­nu­al news con­fer­ence in Basel Get­ty

While Cred­it Su­isse was siz­ing up the amount of over­seas mon­ey that will soon be avail­able to the top buy­ers in bio­phar­ma, their an­a­lysts put to­geth­er a list of top takeover tar­gets, ranked by mar­ket cap. I’m pulling out the top 10 here to go along­side the main sto­ry — for End­points News In­sid­ers — on who has $171 bil­lion to play with, along with sug­ges­tions on how they can spend that mon­ey.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.